Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.

Abstract

Ruxolitinib is a Janus kinase (JAK) inhibitor used for the treatment of myelofibrosis with demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly. Anemia and thrombocytopenia are the main secondary effects. However, there are case reports of rare but serious adverse events following drug withdrawal. We present a case of a 76… (More)
DOI: 10.1007/s12185-014-1628-5

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics